CHAOJU EYE CARE2219.HKValuation Analysis

As of Oct 16, 2026, CHAOJU EYE CARE (2219.HK) trades at a P/E of 8.95x, P/B of 0.63x, P/S of 1.08x, and a dividend yield of 10.04%.
Longitudinal percentile comparison: P/E sits at the 14th percentile over the trailing 10Y window (vs. 26th percentile over 3Y); P/B sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 24th percentile within its industry and the 41st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 11.62%, ranking at the 92nd percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 13.1 points of each other — a consistent signal from both angles. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 11.62% total shareholder yield, 10.04% is paid out as dividends and roughly 1.58% is implied to come from buybacks — both channels are meaningfully in play. CHAOJU EYE CARE operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.